Masuda N, Ohtani S, Takano T, Inoue K, et al. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer. Breast Cancer Res Treat 2020 Jan 17. pii: 10.1007/s10549-020-05524.
PMID: 31953696